HIV/AIDS Topics Preparing for PrEP
- Details
- Category: HIV Prevention
- Published on Wednesday, 23 May 2012 00:00
- Written by Matt Sharp
PrEP (pre-exposure prophylaxis) is a new HIV prevention tool with great possibilities. Matt Sharp, who served as a community representative on the FDA panel that recommended approval of Truvada (tenofovir/emtricitabine) for PrEP, describes the vote and its implications.
May 18 is HIV Vaccine Awareness Day
- Details
- Category: HIV Prevention
- Published on Wednesday, 16 May 2012 00:00
- Written by Liz Highleyman
This Friday, May 18, is HIV Vaccine Awareness Day (HVAD) in the U.S. as well as World AIDS Vaccine Day, an opportunity to raise awareness about the importance of preventive HIV vaccine research and to recognize the many study volunteers, community advocates, health professionals, and researchers who are working to find safe and effective vaccines to reduce the risk of HIV infection.
Long-Term Analysis Confirms Elevated HIV Risk for Some Participants in Step Vaccine Study
- Details
- Category: HIV Prevention
- Published on Tuesday, 08 May 2012 00:00
- Written by Press Release
Extended follow-up provides further data confirming the observed increase in the likelihood of becoming infected with HIV among certain participants in the Step (HVTN 054) HIV vaccine trial.
FDA Advisory Committee Recommends Truvada for Prevention of HIV Sexual Transmission
- Details
- Category: HIV Prevention
- Published on Thursday, 10 May 2012 00:00
- Written by Liz Highleyman
On May 10, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) decisively recommended approval of Truvada -- Gilead Sciences' tenofovir/emtricitabine combination pill -- for pre-exposure prophylaxis (PrEP) to prevent sexual transmission of HIV.
FDA Committee Will Consider Approval of Truvada for HIV PrEP this Thursday
- Details
- Category: HIV Prevention
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
On May 10, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hear evidence regarding the use of the tenofovir/emtricitabine combination pill Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV infection. Gilead Sciences requested approval of the expanded indication in December 2011.
Web Design and Development by